US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic
Executive Summary
Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.
You may also be interested in...
Eager But Wary: Industry Seeks More Useful, More Detailed Remote Regulatory Assessment Processes
Responses to FDA draft guidance suggest more promptness while also more elaborate processes for agency decision making based on remote methods. Questions include what’s voluntary, what’s mandatory, what can be decided remotely, and how to remotely move on from warning letters.
US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups
CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”
Remote Assessments A Welcome Option For US FDA, But They’re Not Every Firm’s First Choice
“We're looking to expand the use of this tool make it a more routine part of our operations going forward,” says Michael Dutcher, deputy director, ORA Office of Human and Animal Food Operations. “In general, the response from industry has been pretty positive” about RRAs.